Salvatore Giovine notified Xilio Therapeutics, Inc. of his decision to resign as chief financial officer of the Company, effective August 19, 2022, for personal family reasons.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.05 USD | +2.94% | -2.78% | +90.91% |
14/05 | Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
19/04 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+90.91% | 38.76M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- XLO Stock
- News Xilio Therapeutics, Inc.
- Xilio Therapeutics, Inc. Announces Resignation of Salvatore Giovine as Chief Financial Officer Effective August 19, 2022